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Publication of data collection forms from
NHLBI funded sickle cell disease
implementation consortium (SCDIC)
registry
Jeffrey A. Glassberg1* , Elizabeth A. Linton1, Katrina Burson2, Tabitha Hendershot2, Joseph Telfair3, Julie Kanter4,
Victor R. Gordeuk5, Allison A. King6, Cathy L. Melvin7, Nirmish Shah8, Jane S. Hankins9, Axel Yannick Epié1,
Lynne D. Richardson1 and for the Sickle Cell Disease Implementation Consortium

Abstract
Background: Sickle cell disease (SCD) is an autosomal recessive blood disorder affecting approximately 100,000
Americans and 3.1 million people globally. The scarcity of relevant knowledge and experience with rare diseases
creates a unique need for cooperation and infrastructure to overcome challenges in translating basic research
advances into clinical advances. Despite registry initiatives in SCD, the unavailability of descriptions of the selection
process and copies of final data collection tools, coupled with incomplete representation of the SCD population
hampers further research progress. This manuscript describes the SCDIC (Sickle Cell Disease Implementation
Consortium) Registry development and makes the SCDIC Registry baseline and first follow-up data collection forms
available for other SCD research efforts.
Results: Study data on 2400 enrolled patients across eight sites was stored and managed using Research Electronic
Data Capture (REDCap). Standardized data collection instruments, recruitment and enrollment were refined through
consensus of consortium sites. Data points included measures taken from a variety of validated sources (PHENX,
PROMIS and others). Surveys were directly administered by research staff and longitudinal follow-up was
coordinated through the DCC. Appended registry forms track medical records, event-related patient invalidation,
pregnancy, lab reporting, cardiopulmonary and renal functions.
Conclusions: The SCDIC Registry strives to provide an accurate, updated characterization of the adult and
adolescent SCD population as well as standardized, validated data collecting tools to guide evidence-based
research and practice.
Keywords: Sickle cell disease, Standardized data collection tools, SCDIC registry forms, Accurate characterization
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Background
Sickle cell disease (SCD) is a rare, autosomal recessive
blood disorder affecting approximately 100,000 individuals in the United States [1] and 3.1 million individuals
worldwide [2]. The scarcity of relevant knowledge and
experience with rare diseases creates a unique need for
cooperation and infrastructure to overcome challenges
in translating basic research advances into clinical
advances. Rare disease registries are characterized by
systematic, longitudinal collection of clinical, genetic,
and biologic data, which can contribute to basic and
translational research efforts to improve clinical care for
individuals with diseases such as SCD [3].
Over the past decade, SCD registry initiatives in community and clinical settings have employed a variety of
methods including electronic-health record abstraction
[4], patient-reported outcomes via online portals [5],
bio-repositories [6, 7], and collection of clinical data during standard-care visits [8–10]. Some of these registries
collect data using validated measures; however, detailed
descriptions of the measure selection process and copies
of final data collection tools are not available, making it
difficult for subsequent researchers to build on previous
efforts. These registry initiatives were often limited to a
single site or community and were not necessarily representative of the larger SCD population.
The Sickle Cell Disease Implementation Consortium
(SCDIC) is a cooperative research program of eight clinical centers, a data coordinating center (DCC), and the
National Heart, Lung, and Blood Institute (NHLBI). The
SCDIC’s structure and goals are described elsewhere
[11]. A key objective of the SCDIC is to develop a registry of at least 2400 adolescents and adults living with
SCD. This manuscript describes the SCDIC Registry development and makes the SCDIC Registry baseline and
first follow-up data collection forms available for other
SCD research efforts.
Materials/methods
The SCDIC Registry seeks to characterize the SCD
population, provide an evidence base to guide research
and practice, and leverage existing, validated tools to
collect standard clinical measures, laboratory values,
lifestyle factors, medical history, treatment, healthcare
utilization, and patient reported outcomes. ASCQ-Me
[12] and PhenX [13] (SCD-specific measures), and PROMIS [14] measures were used to build the SCDIC Registry forms. Candidate measures were considered and
discussed by the SCDIC Registry Subcommittee; selected
measures were included in draft data collection forms
reviewed by the SCDIC Steering Committee. Standardized data collection forms, and recruitment and enrollment procedures were iteratively refined until consensus
was achieved among the consortium sites and NHLBI
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program staff. Additional file 1 outlines a flow diagram
detailing the consortium and study steps towards data
collection. Table 1 outlines the SCDIC Registry Timeline. Registry forms and procedures were approved by
Institutional Review Boards at each participating
institution.
Inclusion criteria

Participants in the SCDIC Registry must be 15 years to
45 years of age and have laboratory confirmed diagnosis
of SCD: Hb SS, Hb SC, Hb Sβ-thalassemia, Hb SO, Hb
SD, Hb SG, Hb SE, or Hb SF. Participants (or consenting
guardian) must have a basic command of English, be
willing and cognitively able to give informed consent or
assent, and be able to answer questions on the patient
enrollment survey.
Exclusion criteria

Persons unwilling or unable to complete the enrollment
survey, persons with sickle cell trait (carriers – Hb AS)
and those with a successful bone marrow transplant, are
excluded.

Results
From December 2016 through May 2019, over 2400
adolescents and adults living with SCD were enrolled in
the SCDIC Registry across the consortium’s eight clinical
sites. All sites reached their goal of 300 enrolled participants and completed baseline data files on each of them.
Baseline demographic characteristics, patient reported
outcomes, and experiences with SCD-related pain of this
cohort are detailed elsewhere [15]. The SCDIC Registry’s
baseline and first follow-up data collection procedures
and forms are described below. Study data were collected and managed using REDCap (Research Electronic
Data Capture) electronic data capture tools hosted at the
DCC. REDCap is a secure, web-based application designed to support research study data collection [16].
The SCDIC registry baseline and first follow-up paper
forms and REDCap data dictionary are available in the
Supplemental Appendices (Additional file 2). Each site
employed its own methods to maximize success with
longitudinal follow up. Strategies included preset
reminders for form completion in REDCap, capturing
followup data at routine care appointments, telephone
calls to collect survey data, and text message reminders.
Patient registration form

This form tracks the method of survey administration
(interview vs. self-administered), confirmation of the
diagnosis of SCD, and basic demographics. Diagnosis
status was confirmed by newborn screening, hemoglobin
fractionation, hemoglobin electrophoresis or DNA sequencing. Participants are categorized as affiliated or
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Table 1 SCDIC Registry timeline
Phase I

Phase II

Year 1
Q1

Q2

Year 2
Q3

Finalize core measures

X

Develop procedures

X

X

Design data forms

X

X

Protocol development

Q4

Q1

Q3

Q4

Q1

Years 4–6

Q2

Q3

Q4

Y4

Y5

Y6

ADMINISTRATIVE REVIEW

X

X

Secure IRB approvals

X

X

Develop data systems

X

X

Manual of operations

X

X

Train coordinators

X

Recruitment and follow-up

X

Monitoring

Q2

Year 3

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Data analysis and publication

unaffiliated; unaffiliated is defined as not having seen a
SCD provider in a non-acute setting in the past 2 years,
excluding the enrollment visit.
Patient enrollment survey form

This form comprises the core of the SCDIC Registry
data, covering eight key domains: (1) pain history, (2)
hydroxyurea use, (3) blood transfusions, (4) medical history, (5) current medications, (6) barriers to medical
care, (7) social and mental health, and (8) detailed demographics. Referent timeframes used measured participants’ chronic and recent SCD-related pain experiences.
Questions adapted from published measures maintained
face validity, but were not reassessed for construct validity. Table 2 documents the measures reviewed, selected,
and adapted. Table 2 documents the measures reviewed,
selected, and adapted. In choosing the final measures,
the consortium committee sought to avoid redundancy,
maximize face and content validity and prioritize measures most likely to be relevant for future research.
Patient follow-up survey form

Longitudinal follow-up is scheduled to occur annually.
The follow-up survey is an abbreviated version of the
patient enrollment survey and can be administered in
person, by phone, by mail, or via an online survey. Three
centers are also administering a short questionnaire to
obtain the number of adverse events adult participants
experienced before turning 18 years old.
Pregnancy and conception forms

These forms provide information about participants’
conception and pregnancy history, including medical
complications, use of hydroxyurea, live births, and fertility treatments (if any) and were designed to capture the

impact of hydroxyurea use on reproductive health,
especially conception and birth outcomes.
Medical record abstraction form

Medical record abstraction is completed by research staff
for participants with available medical records. Demographics, diagnosis, anthropometric measurements,
organ systems review, and treatment are included. A list
of definitions used by registry coordinators conducting
medical record abstraction is in the Supplemental
Appendices.
Laboratory reporting form

Research staff record the most recent test results at a
time the participant was in steady state – defined as at
least 2 weeks before or after blood transfusions, vasoocclusive pain crisis, priapism, stroke, or other acute
event.
Renal form

Research staff complete this form for enrolled participants whose medical abstraction form contains a “Yes”
response to Q35 (chronic kidney disease) or Q41 (end
stage renal disease). Results are the most recent available
within 5 years of the date of consent.
Pulmonary hypertension and left ventricular dysfunction
form

Research staff complete this form for enrolled participants whose medical abstraction form contains a “Yes”
response to Q40 (pulmonary hypertension) or Q41 (left
ventricular dysfunction). Results are the most recent
available within 5 years of the date of consent.
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Table 2 Measures reviewed, selected, and adapted for SCDIC Registry Patient Enrollment Survey Form
Reviewed

Selected

ASCQ-Me Pain

Yes

Yes

ASCQ-Me Pain Episode Frequency and Severity

Yes

Yes

ASCQ-Me Stiffness Impact

Yes

No

ASCQ-Me Sleep Impact

Yes

Partial

ASCQ-ME Sickle Cell Medical History Checklist

Yes

Yes

ASCQ-Me Emotional Impact

Yes

Partial

ASCQ-Me Social Functioning Impact

Yes

Yes

PhenX Frequency of Sickle Cell Pain Episodes Per Year

Yes

No

PhenX History of Transfusion

Yes

Yes

PROMIS Pain Intensity

Yes

No

PROMIS Fatigue

Yes

Yes

PROMIS Pain Interference

Yes

No

PROMIS Sleep Disturbance

Yes

No

PROMIS-29 Profile (adult)

Yes

Partial

Neuro-QOL Cognitive Function

Yes

Yes

PROMIS PQ-Neuro

Yes

Partial

PROMIS Global Health

Yes

No

Off study form

Research staff complete this form for participants who
experience an event that invalidates them from followup data collection. Cause of death and autopsy reports
(if available) are documented for registry participants
who died.

Discussion
Similar studies have characterized SCD populations and
provided a wider knowledge base via which the research
community could collaborate. The Cooperative Study of
Sickle Cell Disease (CSSCD) recruited from 27 sites and
provided a frequency of various socioeconomic factors
as they relate to mortality and morbidity in this disease
population [17]. Unlike the SCDIC and Sickle Cell
Clinical Research and Intervention Program (SCCRIP), it
had less inclusive criteria, no organ system function
analysis or recruitment of patients exposed to disease
treatment [18].
SCCRIP like the SCDIC prospectively recruited diagnosed sickle cell disease patients across multiple developmental cohorts (newborn to older adult). It collected
clinical, social and health outcomes data for proper
characterization of this population with the goal of
furthering genomic and proteomic research via identification of treatment-contributing biomarkers [18].
Although similar, the SCDIC has almost twice the sample size, incorporates more validation tools and information systems without requiring a concept proposal for
data use, likely making it more publicly accessible. Researchers publishing data using SCDIC forms simply

Adaptations

Kept items 1 and 3

Kept items 1 and 5

Kept depression items

Kept item 3

need to acknowledge the Consortium as follows: “Data
collection instruments were (used/modified) from those
developed under the Sickle Cell Disease Implementation
Consortium supported by cooperative agreements from
the National Heart, Lung, and Blood Institute and the
National Institute on Minority Health and Health Disparities (Bethesda, MD).”
The appended SCDIC Registry forms are of value to
SCD research efforts as they (1) are a public resource to
facilitate a more modern understanding of this rare disease and its effects on people living with it, (2) are developed from validated measures with broad consensus
from SCD and implementation science research experts
across the country, (3) form a platform for clinical
characterization of people living with SCD in both observational and interventional studies, (4) allow future
harmonization of data across studies, and (5) may facilitate mechanistic and therapeutic discoveries in SCD and
perhaps other rare diseases. SCDIC registry REDCap
data dictionary publication reduces researcher and logistical burden associated with building electronic data capture systems for SCD research.
Data from the SCDIC Registry may serve as a “control”
for additional intervention studies, especially when
comparison to people living with SCD exposed to hydroxyurea is intended. Additionally, the SCDIC Registry
data collection forms serve as a template for new
prospective studies in SCD. Information collected on
enrolled participants may lead to new potential biomarkers and social determinants for specific outcomes
in SCD or allow for the identification of novel study
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questions. Finally, the SCDIC Registry data will offer an
updated description of adolescents and adults with SCD
in the United States and may be useful in benchmarking
future studies.

Conclusions
Rare disease registries are characterized by systematic,
longitudinal collection of clinical, genetic, and biologic
data, which can contribute to basic and translational research efforts to improve clinical care for individuals
with diseases such as SCD. The registry forms provided
by this study stem from SCD expert-validated measures
and may be useful to other researchers conducting interventional or observational studies to further understanding of this disease and its population.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-01457-x.
Additional file 1. Sickle Cell Disease Implementation Consortium flow
diagram is provided here.
Additional file 2:. “Publication of data collection forms from NHLBI
funded Sickle Cell Disease Implementation Consortium (SCDIC) Registry:
Supplemental Appendices”. The detailed data collection forms
mentioned in the results are provided here.
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